Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (NASDAQ: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 983 restricted stock units (RSUs) to two newly-hired employees as inducement awards. The RSUs were granted on April 30, 2025, under the company's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over a three-year period, with 33 1/3% vesting annually on the grant date anniversary, contingent on continued employment. In case of a change in control event, the RSUs will fully vest if the employee is terminated for "good reason" or without "cause" within one year of the event.
Karyopharm Therapeutics (NASDAQ: KPTI), un'azienda farmaceutica in fase commerciale specializzata in terapie oncologiche, ha assegnato 983 unità di azioni vincolate (RSU) a due nuovi dipendenti come premio di incentivazione. Le RSU sono state concesse il 30 aprile 2025, nell'ambito del Piano di Incentivazione Azionaria 2022 dell'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Le RSU matureranno nel corso di un periodo di tre anni, con il 33 1/3% che matura ogni anno nell'anniversario della data di concessione, subordinatamente alla continuità dell'impiego. In caso di un evento di cambio di controllo, le RSU matureranno completamente se il dipendente viene licenziato per "giusta causa" o senza "motivo" entro un anno dall'evento.
Karyopharm Therapeutics (NASDAQ: KPTI), una empresa farmacéutica en etapa comercial enfocada en terapias contra el cáncer, ha otorgado 983 unidades restringidas de acciones (RSU) a dos empleados recién contratados como premios de incentivo. Las RSU fueron otorgadas el 30 de abril de 2025, bajo el Plan de Incentivos de Acciones por Incentivo 2022 de la compañía, cumpliendo con la Regla de Listado Nasdaq 5635(c)(4).
Las RSU se consolidarán a lo largo de un período de tres años, con un 33 1/3% consolidándose anualmente en el aniversario de la fecha de concesión, condicionado a la continuidad del empleo. En caso de un evento de cambio de control, las RSU se consolidarán completamente si el empleado es despedido por "buena causa" o sin "causa" dentro del año siguiente al evento.
Karyopharm Therapeutics (NASDAQ: KPTI)는 암 치료에 중점을 둔 상업 단계 제약 회사로, 두 명의 신입 직원에게 983개의 제한 주식 단위(RSU)를 유인 보상으로 부여했습니다. RSU는 2025년 4월 30일 회사의 2022년 유인 주식 인센티브 계획에 따라 부여되었으며, 나스닥 상장 규칙 5635(c)(4)를 준수합니다.
RSU는 3년 기간에 걸쳐 베스팅되며, 매년 부여일 기념일에 33 1/3%씩 베스팅되며 계속 고용 중인 경우에 한합니다. 지배권 변경 이벤트 발생 시, 직원이 "정당한 사유" 또는 "사유 없음"으로 해당 이벤트 후 1년 이내에 해고될 경우 RSU는 전액 베스팅됩니다.
Karyopharm Therapeutics (NASDAQ: KPTI), une société pharmaceutique en phase commerciale spécialisée dans les thérapies contre le cancer, a accordé 983 unités d'actions restreintes (RSU) à deux employés récemment embauchés en tant que récompenses d'incitation. Les RSU ont été attribuées le 30 avril 2025, dans le cadre du Plan d'Incitation en Actions 2022 de la société, conformément à la règle de cotation Nasdaq 5635(c)(4).
Les RSU seront acquises sur une période de trois ans, avec 33 1/3 % acquises chaque année à l'anniversaire de la date d'attribution, sous réserve de la poursuite de l'emploi. En cas de changement de contrôle, les RSU seront entièrement acquises si l'employé est licencié pour "bonne cause" ou sans "motif" dans l'année suivant l'événement.
Karyopharm Therapeutics (NASDAQ: KPTI), ein pharmazeutisches Unternehmen in der kommerziellen Phase mit Schwerpunkt auf Krebstherapien, hat 983 Restricted Stock Units (RSUs) an zwei neu eingestellte Mitarbeiter als Anreizprämien gewährt. Die RSUs wurden am 30. April 2025 im Rahmen des Inducement Stock Incentive Plans 2022 des Unternehmens gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
Die RSUs werden über einen drei Jahre andauernden Zeitraum vesten, wobei jährlich zum Jahrestag der Gewährung 33 1/3 % vesten, vorbehaltlich einer fortgesetzten Anstellung. Im Falle eines Kontrollwechsels vesten die RSUs vollständig, wenn der Mitarbeiter innerhalb eines Jahres nach dem Ereignis aus "gutem Grund" oder ohne "Ursache" entlassen wird.
- None.
- None.
Each RSU award will vest over three years, with 33 1/
In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302441806.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
What type of RSU grants did Karyopharm Therapeutics (KPTI) announce on May 1, 2025?
What is the vesting schedule for KPTI's RSU grants announced in May 2025?
What happens to KPTI's RSU grants in case of a change in control event?
Under which Nasdaq rule did Karyopharm issue these RSU grants?
